通策医疗股份有限公司发布股份回购进展公告，或对股价产生积极影响
关键要点概述
- 回购方案首次披露日期：2026年6月4日
- 回购方案实施期限：2026年6月26日至2027年6月25日
- 回购金额区间：5,000万元至10,000万元
- 回购用途：用于减少注册资本（即注销回购股份）
- 累计已回购股份：1,447,422股，占总股本0.3236%
- 累计已回购金额：50,052,228.03元
- 实际回购价格区间：33.53元/股至35.71元/股
详细内容与投资者关注事项
通策医疗股份有限公司（600763）于2026年7月24日发布了最新股份回购进展公告。此次回购方案已于2026年6月4日首次披露，并在第十届董事会第十四次会议及2025年年度股东大会通过，明确将通过上海证券交易所集中竞价交易方式回购公司股份。回购价格不高于60.12元/股，回购资金总额不低于5,000万元且不超过10,000万元，回购期限为12个月。
截至公告日，公司已通过集中竞价方式回购股份1,447,422股，占公司总股本的0.3236%。实际成交价格区间为33.53元/股至35.71元/股，已支付资金总额为50,052,228.03元（未包含印花税及交易佣金等费用），已超过回购计划的下限。
本次回购股份全部用于注销，减少公司注册资本。如此大规模回购并注销股份，意味着公司的流通股本将减少，理论上每股盈利（EPS）将提升，具有明显的利好作用，或对公司股价形成积极支撑。此外，公司回购股份的资金已到位且进度超出计划下限，显示公司现金流状况良好，管理层对未来发展充满信心。
公司承诺严格按照《上市公司股份回购规则》和相关监管指引，在回购期限内根据市场情况择机实施回购，并将持续及时披露回购进展。投资者需注意，公司仍将根据后续市场情况继续实施回购，后续进展可能会持续影响公司股价。
可能影响股价的重要因素
- 回购股份全部用于注销，减少注册资本，提升每股盈利和股东价值。
- 回购计划已超额完成下限，显示公司财务状况稳健，管理层信心强。
- 后续回购进展将持续披露，投资者需关注公司回购进度与市场反应。
投资者特别提示
股份回购及注销属于重大利好事项，通常会对股价形成支撑和提升；但投资者需关注公司回购的持续性及市场整体环境变化，谨慎投资。
免责声明：本文内容仅供参考，不构成任何投资建议。投资者请结合自身情况和市场风险，理性决策。
Tongce Medical Co., Ltd. Announces Progress on Share Buyback, Potentially Positive for Share Price
Key Highlights
- Initial disclosure date of buyback plan: June 4, 2026
- Buyback implementation period: June 26, 2026 to June 25, 2027
- Buyback amount range: RMB 50 million to RMB 100 million
- Purpose of buyback: Reduction of registered capital (i.e., shares bought back will be cancelled)
- Total shares already bought back: 1,447,422 shares, accounting for 0.3236% of total share capital
- Total buyback amount: RMB 50,052,228.03
- Actual buyback price range: RMB 33.53/share to RMB 35.71/share
Detailed Content and Investor Considerations
Tongce Medical Co., Ltd. (600763) released an update on its share buyback progress on July 24, 2026. The buyback plan was first disclosed on June 4, 2026, and approved at the 14th meeting of the 10th Board of Directors and the 2025 Annual General Meeting. The company will repurchase shares through centralized bidding on the Shanghai Stock Exchange, at a price not exceeding RMB 60.12/share, with a total buyback fund of no less than RMB 50 million and no more than RMB 100 million. The buyback period spans 12 months.
As of the announcement date, the company has repurchased 1,447,422 shares via centralized bidding, accounting for 0.3236% of total share capital. The actual transaction price range was RMB 33.53/share to RMB 35.71/share, for a total payment of RMB 50,052,228.03 (excluding stamp duty and transaction commissions), which exceeds the lower limit set in the buyback plan.
All repurchased shares will be cancelled, reducing the company’s registered capital. This large-scale repurchase and cancellation will reduce the number of outstanding shares, theoretically boosting earnings per share (EPS) and shareholder value—an obvious positive for share price. The fact that the company has already exceeded the lower limit of its buyback plan demonstrates strong cash flow and management confidence in future development.
The company pledges to strictly follow relevant rules and guidelines, and will continue to make buyback decisions based on market conditions within the buyback period, with timely disclosures. Investors should note that the buyback will continue, and further progress may influence share price.
Price-Sensitive Factors
- All repurchased shares will be cancelled, reducing registered capital and increasing EPS and shareholder value.
- Buyback progress already exceeds lower limit, indicating sound financial position and strong management confidence.
- Further buyback progress will be disclosed; investors should monitor ongoing buybacks and market reactions.
Investor Advisory
Share buyback and cancellation is generally a major positive, often supporting and boosting share price. However, investors should monitor the ongoing buyback and overall market environment, and make decisions prudently.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should make decisions based on their own circumstances and market risks.
